Pharmaceutical spin-off AbbVie recently received a big upgrade from Wall Street bank Morgan Stanley, sending shares up 6% last week. In this video, health-care analyst David Williamson breaks down what investors need to know about this bullish report, and why they might want to show caution before buying AbbVie stock.